Biomarkers for Systemic Therapy in Metastatic Breast Cancer
Key Points
Key Points
Testing for ESR1, PIK3CA, AKT1 and inactivation of PTEN somatic variants and germline BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) pathogenic variants (mutations) to guide therapy.
Testing tumors for homologous recombination deficiency, expression of programmed cell death ligand-1 (PD-L1), deficient mismatch repair microsatellite instability (dMMR/MSI), tumor mutational burden (TMB), neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and trophoblast cell-surface antigen 2 (TROP2) expression to determine eligibility for selected treatments.
The use of cell-free, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for monitoring treatment response.
Treatment
...atment...
...mmendations from 2024 Rapid Recommendat...
...ion 1.1The Expert Panel recommends multiple lines...
...ation 1.2There are no comparative effica...
...Treatment Options According to Prior Endocrine T...
...ions from 2023 Rapid Recommendation...
...in treatment selection, the Expert Panel recommend...
Patients previously treated with ET a...
...mmendations from 2022 Focused Guideline Update...
...n 1.1Patients with locally recurren...
....1Patients with metastatic HER2-nega...
...tion 3.2There is insufficient evidence to s...
...n 4.1There are insufficient data at present...
...commendation 5.1Patients with locally recurrent u...
...ation 6.1Patients with metastatic cancer who ar...
...ndation 7.1Patients with metastatic can...
...n 8.1Clinicians may test for NTRK...
...ndation 9.1There are insufficient data...
...10.1There are insufficient data to recom...
...n 11.1There are insufficient data to recommend ro...
...ecommendations Unchanged From 20...
...l presentation of metastasis from breast can...
...dation for Tissue Biomark...
...s who are already receiving systemic therap...
...commendations for Circulating Tumor Markers
...patients already receiving systemic therapy for...
...inoembryonic antigen (CEA), cancer antige...
...e to ASCO Biomarker Testing in Metastatic...
...Tests Recommended by the ASCO Expert PanelHaving...
...er Tests Not Recommended by the ASC...
.... At-A-Glance Guide to ASCO Biomarker Testing in M...
...At-A-Glance Guide to ASCO Biomarker Testing in M...
...eves that cancer clinical trials are vital...